464 related articles for article (PubMed ID: 23799530)
1. Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.
Blennow K; Hampel H; Zetterberg H
Neuropsychopharmacology; 2014 Jan; 39(1):189-201. PubMed ID: 23799530
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers in Alzheimer's disease drug development.
Cummings JL
Alzheimers Dement; 2011 May; 7(3):e13-44. PubMed ID: 21550318
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
[TBL] [Abstract][Full Text] [Related]
4. Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.
Cribbs DH
CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):207-16. PubMed ID: 20205639
[TBL] [Abstract][Full Text] [Related]
5. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
[TBL] [Abstract][Full Text] [Related]
6. Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention.
Tarawneh R; Holtzman DM
CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):144-59. PubMed ID: 19355934
[TBL] [Abstract][Full Text] [Related]
7. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
8. Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.
Hampel H; Shen Y; Walsh DM; Aisen P; Shaw LM; Zetterberg H; Trojanowski JQ; Blennow K
Exp Neurol; 2010 Jun; 223(2):334-46. PubMed ID: 19815015
[TBL] [Abstract][Full Text] [Related]
9. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.
Hampel H; Bürger K; Teipel SJ; Bokde AL; Zetterberg H; Blennow K
Alzheimers Dement; 2008 Jan; 4(1):38-48. PubMed ID: 18631949
[TBL] [Abstract][Full Text] [Related]
10. Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease.
Ruthirakuhan M; Herrmann N; Suridjan I; Abraham EH; Farber I; Lanctôt KL
Expert Opin Pharmacother; 2016 Dec; 17(18):2417-2429. PubMed ID: 27825018
[TBL] [Abstract][Full Text] [Related]
11. Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.
Doecke JD; Rembach A; Villemagne VL; Varghese S; Rainey-Smith S; Sarros S; Evered LA; Fowler CJ; Pertile KK; Rumble RL; Trounson B; Taddei K; Laws SM; Macaulay SL; Bush AI; Ellis KA; Martins R; Ames D; Silbert B; Vanderstichele H; Masters CL; Darby DG; Li QX; Collins S;
J Alzheimers Dis; 2018; 61(1):169-183. PubMed ID: 29171991
[TBL] [Abstract][Full Text] [Related]
12. Integrating ADNI results into Alzheimer's disease drug development programs.
Cummings JL
Neurobiol Aging; 2010 Aug; 31(8):1481-92. PubMed ID: 20447734
[TBL] [Abstract][Full Text] [Related]
13. Towards the Integrative Theory of Alzheimer's Disease: Linking Molecular Mechanisms of Neurotoxicity, Beta-amyloid Biomarkers, and the Diagnosis.
Molkov YI; Zaretskaia MV; Zaretsky DV
Curr Alzheimer Res; 2023; 20(6):440-452. PubMed ID: 37605411
[TBL] [Abstract][Full Text] [Related]
14. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.
Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH
Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials.
Menéndez-González M; Pérez-Piñera P; Martínez-Rivera M; Muñiz AL; Vega JA
Curr Pharm Des; 2011; 17(5):508-20. PubMed ID: 21375481
[TBL] [Abstract][Full Text] [Related]
16. Amyloid-beta immunotherapy for Alzheimer's disease.
Fu HJ; Liu B; Frost JL; Lemere CA
CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):197-206. PubMed ID: 20205640
[TBL] [Abstract][Full Text] [Related]
17. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
18. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
19. Amyloid biomarkers in Alzheimer's disease.
Blennow K; Mattsson N; Schöll M; Hansson O; Zetterberg H
Trends Pharmacol Sci; 2015 May; 36(5):297-309. PubMed ID: 25840462
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers as Endpoints in Clinical Trials for Alzheimer's Disease.
Elghanam Y; Purja S; Kim EY
J Alzheimers Dis; 2024; 99(2):693-703. PubMed ID: 38669547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
